Innovation Advisory Committee.
Due Diligence
IAC
The Innovation Advisory Committee (IAC) will advise on financial investments for the advancement of technologies that 1) address dire gaps in the standard of care for people who are at risk or diagnosed with cancer; and 2) demonstrate a clear path to patient access.
Regina Leung
Regina is currently Chief Business Officer at CSSi Lifesciences, a consulting firm that provides regulatory support to clients. Regina is also the Founder of MayFlower Health, a consulting firm that supports commercialization strategies including brand, managed markets and market entry for pharmaceutical and medical devices companies. Prior to MayFlower Health, Regina worked in commercial roles within large biopharmaceutical companies such as Bristol-Myers Squibb, PDL Pharma, and Gilead Sciences, as well as at McKesson, a global life sciences distributor where she started the first generic drugs portfolio program for the hospital market and holds a patent for an oncology practice management solution. Regina also worked as a market access Principal at IQVIA and CapGemini, headed their West Coast business and supported market access strategies for large brands including Enbrel, Aimovig and Actemra and medical devices such as Dexcom.
Andy Fisch
Andy is a frequent speaker at industry and client events. Known for expertise across many asset classes, top-down analysis and a successful global investor. His skills and experience span the globe, from capital markets to corporate structure, technology both as tools and investments, broadly defined from semiconductors to biotech, quantitative and fundamental investment approaches. Decades with family offices plus more than a decade as an institutional investor, numerous committees, corporate boards and held FINRA 24 and 7 principal licenses. A disciplined, common-sense investor, building on information, an aversion to “following the crowd” and attention to detail.
His 40 years investing experience exclusively in “buy-side” activities within alternatives, trading, hedge and venture capital. Two decades investing on behalf of Swiss family and multi-family offices, then 12 years as a CIO of a global institutional hedge FOF and back again with mostly Euro family offices. From the beginning he built his own research and trading software, leading to then investing in technology both public and progressively towards private companies. All combined with a top-down macroeconomic and geopolitical framework, particularly cycle aware.
